Abstract:Preclinical and clinical studies have shown that intratumoral oncolytic viruses (OVs) can convert "cold" tumors to "hot" and overcome resistance to immune checkpoint blockade. However, their modest clinical efficacy to date highlights major gaps in our understanding of how OVs interact with the immune system, and very limited information is available regarding the specificity of the T cell repertoires that emerge within tumors in response to OV therapy. To address these gaps, we interrogated the evolution of immune response to OV therapy in mice using oncolytic Newcastle Disease Virus (NDV). Leveraging a bilateral flank melanoma mouse model, we identified and phenotypically characterized anti-viral and anti-tumor T cells in local and abscopal tumors with single cell (sc) RNA and T cell receptor (TCR) sequencing. Intratumoral NDV therapy to a single flank tumor resulted in increased infiltration of CD4+ and CD8+ T cells in both the injected and distant tumors, higher TCR overlap between treated and distant tumors, and higher frequency of convergent TCR clonotypes, suggesting their non-random expansion, albeit without specificity information. To identify the specificity of the emergent TCR clones in an unbiased fashion, we developed an approach based on adoptive transfer of T cells from tumor-bearing control or NDV-treated donor mice into congenically marked recipients with either B16 or NDV antigen stimulation. This allowed the isolation and identification of expanded B16- or virus-specific TCR clones that were then linked to donor tumors to define their relative frequencies, their distribution across the treated and distant tumors, and their associated phenotypic states. We observed significantly greater expansion of B16-reactive T cells adoptively transferred from NDV-treated donors (compared to control donors), suggesting that NDV therapy leads to potentiation of tumor-specific immune response. Intriguingly, virus-specific and tumor-specific T cells appeared to distribute to distinct phenotypic clusters, with virus-specific and tumor-specific T cells found predominantly in the activated-dysfunctional and proliferating clusters, respectively. When looking at the distribution of the TCR clones, virus-specific clones dominated the majority of the response in both treated and distant tumors, despite the lack of virus injection in distant tumors. These results provide insights into understanding the balance between virus- and tumor-directed immune responses elicited by OV therapy and highlight that even in the presence of significant abscopal immune effect, the significant proportion of T cells in "hot" tumors represent anti-viral rather than anti-tumor response. These findings provide tools for tracking of immune response specificity and generate rationale for development of OV engineering strategies and combinations that favor anti-tumor rather than anti-viral immunity. Citation Format: Olga Lyudovyk, Bharat Burman, Nicholas Ceglia, Benjamin Greenbaum, Yuval Elhanati, Dmitriy Zamarin. Evolution of anti-viral and anti-tumor immunity in tumors in response to oncolytic virus therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB400.

Quantitative Virus-Associated RNA Detection to Monitor Oncolytic Adenovirus Replication

In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

RESEARCH ON DISSEMINATION OF RECOMBINANT ADENOVIRUS INTRA-TUMOR INJECTION IN HUMAN BODY

Expediting adenovirus titer assays via an algorithmic live-cell imaging technique

The Spatial and Single-Cell Analysis Reveals Remodeled Immune Microenvironment Induced by Synthetic Oncolytic Adenovirus Treatment.

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy

Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System

Enhancing the Antitumor Efficacy of Oncolytic Adenovirus Through Sonodynamic Therapy-Augmented Virus Replication

Abstract LB400: Evolution of anti-viral and anti-tumor immunity in tumors in response to oncolytic virus therapy

Virus-Protein Corona Replacement Strategy to Improve the Antitumor Efficacy of Intravenously Injected Oncolytic Adenovirus

Adenovirus-mediated Gene Expression Imaging to Directly Detect Sentinel Lymph Node Metastasis of Prostate Cancer

Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus

An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer

Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401

Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer

Longitudinal Monitoring of the Effects of Anti-Adenoviral Treatment Regimens in a Permissive In Vivo Model

Engineering Oncolytic Adenoviruses with VSVG‐Decorated Tumor Cell Membranes for Synergistically Enhanced Antitumor Therapy

Tumor targeted inflammation and coagulation following oncolytic virus therapy compromises blood flow and triggers apoptosis of uninfected tumor cells

Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors with Low Coxsackie and Adenovirus Receptor.

Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions